APOE and atherosclerosis: PF-06260933 was administered to Apoe−/− mice (10 mg kg−1 b.i.d.)for 6 weeks concomitant with WD, and atherosclerosis lesion development was markedly reduced in the treated mice compared with those that were administered vehicle only (8.0% versus 5.5%; Fig. 7a–c).